<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30404920</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1083-351X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>The Journal of biological chemistry</Title>                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>            </Journal>            <ArticleTitle>Polyamine synthesis as a target of MYC oncogenes.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">jbc.TM118.003336</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.TM118.003336</ELocationID>            <Abstract>                <AbstractText>This paper is in recognition of the 100th birthday of Dr. Herbert Tabor, a true pioneer in the polyamine field for over 70 years, who served as the editor-in-chief of the <i>Journal for Biological Chemistry</i> from 1971 to 2010. We review current knowledge of MYC proteins (c-MYC, MYCN, and MYCL) and focus on <i>ornithine decarboxylase 1</i> (<i>ODC1</i>), an important <i>bona fide</i> gene target of MYC and encoding the sentinel, rate-limiting enzyme in polyamine biosynthesis. Although notable advances have been made in designing inhibitors against the &quot;undruggable&quot; MYC, its downstream targets and pathways are currently the main avenue for therapeutic anticancer interventions. To this end, the MYC-ODC axis presents an attractive target for managing cancers such as neuroblastoma, a pediatric cancer in which <i>MYCN</i> gene amplification correlates with poor prognosis and high-risk disease. ODC and polyamine levels are often up-regulated and contribute to tumor hyperproliferation, especially of MYC-driven cancers. We therefore had proposed to repurpose Î±-difluoromethylornithine (DFMO), an FDA-approved, orally available ODC inhibitor, for management of neuroblastoma, and this intervention is now being pursued in several clinical trials. We discuss the regulation of ODC and polyamines, which besides their well-known interactions with DNA and tRNA/rRNA, are involved in regulating RNA transcription and translation, ribosome function, proteasomal degradation, the circadian clock, and immunity, events that are controlled by MYC proteins.</AbstractText>                <CopyrightInformation>Published under license by The American Society for Biochemistry and Molecular Biology, Inc.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bachmann</LastName>                    <ForeName>Andre S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>CHM -Dept of Pediatrics and Human Development, Michigan State University, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Geerts</LastName>                    <ForeName>Dirk</ForeName>                    <Initials>D</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-6386-8187</Identifier>                    <AffiliationInfo>                        <Affiliation>Medical Biology, University of Amsterdam, Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Biol Chem</MedlineTA>            <NlmUniqueID>2985121R</NlmUniqueID>            <ISSNLinking>0021-9258</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">DFMO</Keyword>            <Keyword MajorTopicYN="N">MYC</Keyword>            <Keyword MajorTopicYN="N">Myc (c-Myc)</Keyword>            <Keyword MajorTopicYN="N">Neuroblastoma clinical trials</Keyword>            <Keyword MajorTopicYN="N">ODC</Keyword>            <Keyword MajorTopicYN="N">cancer</Keyword>            <Keyword MajorTopicYN="N">circadian clock</Keyword>            <Keyword MajorTopicYN="N">glycolysis</Keyword>            <Keyword MajorTopicYN="N">neuroblastoma</Keyword>            <Keyword MajorTopicYN="N">polyamine</Keyword>            <Keyword MajorTopicYN="N">polyamines</Keyword>            <Keyword MajorTopicYN="N">proteasome</Keyword>            <Keyword MajorTopicYN="N">translation</Keyword>            <Keyword MajorTopicYN="N">translation initiation factor</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30404920</ArticleId>            <ArticleId IdType="pii">TM118.003336</ArticleId>            <ArticleId IdType="doi">10.1074/jbc.TM118.003336</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>